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ways. Thus, confounding factors for
the association between resistance
and death may differ for E. faecium
and S. aureus, and analysis of the 2
organisms should be conducted sepa-
rately. This is consistent with the
results of Kaye et al. who showed that
the effect of resistance was higher for
S. aureus (odds ratio [OR] 3.4) than
for E. faecium (OR 2.5) by using sep-
arate analyses to show death rates (9).
Furthermore, these researchers found
different confounding factors in the
adjusted analysis of S. aureus than in
the adjusted analysis of E. faecium.
Because of the need to conduct sepa-
rate analyses, which reduced our sta-
tistical power, our study was ultimate-
ly unable to show a difference in
death rates if it existed. 
In summary, future studies meas-
uring the impact of antimicrobial
resistance on death rates should be
restricted to a specific type of infec-
tion cause by a single organism in a
uniform setting using a validated sys-
tem to predict mortality in that setting.
As such, future studies should involve
multiple study sites.
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Antimicrobial
Resistance in
Campylobacter
To the Editor: Iovine and Blaser
(1) write, “This therapeutic use [of
enrofloxacin] was withdrawn (2) but
is now under appeal” and “Despite the
restrictions on enrofloxacin use,
emergence of fluoroquinolone-resist-
ant  Campylobacter  species, with
poultry as an important source, has
been documented in the United
States… Therefore, our conclusion
remains: use of enrofloxacin in poul-
try materially contributed to increase
in human infection by fluoro-
quinolone-resistant  Campylobacter
species.”
These claims propagate the fol-
lowing important errors. First, the
therapeutic use of enrofloxacin was
not withdrawn. Judge Davidson’s
order to withdraw the approval was an
initial decision, to which exceptions
were filed in 2004. A final decision
rests with the US Food and Drug
Administration Commissioner.
Second, poultry has not been iden-
tified as an important source of fluo-
roquinolone resistance in human
Campylobacter isolates. The raw data
of the cited Smith et al. article (3)
indicate a nonsignificant negative
association between chicken con-
sumption and fluoroquinolone resist-
ance in human isolates. Substantial
resistance levels in Northern
Hemisphere countries with and with-
out enrofloxacin use, which occurred
well before fluoroquinolones were
ever used in animals (3–5), also sug-
gest that attribution of such resistance
to enrofloxacin is simplistic. 
Finally, rational decision-making is
based on probable future consequences
of a decision, not past history or caus-
es of the current situation. Iovine and
Blaser’s claim, “Thus the decision to
withdraw therapeutic use of
enrofloxacin (3) was warranted,” is not
implied, even if enrofloxacin use
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 6, June 2005 983LETTERS
caused the emergence of fluoro-
quinolone resistance. If withdrawing
enrofloxacin increases campylobacte-
riosis from airsacculitis-positive chick-
ens, withdrawal may greatly harm
human health. A rational withdrawal
decision cannot be justified. In sum-
mary, Iovine and Blaser’s view that
enrofloxacin should be banned is not
supported by the data that they have
cited or by principles of sound risk
management and decision-making.
Louis Anthony Cox, Jr.,* Dennis
Copeland,† and Michael Vaughn†
*Cox Associates, Denver, Colorado, USA;
and †Bayer HealthCare, Shawnee,
Kansas, USA
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In Reply: Cox and colleagues
raised 3 major points. For the first
point, we stated (1) “This therapeutic
use was withdrawn but is now under
appeal.” The actual language of US
Federal Drug Administration Judge
Davidson’s ruling is “Enrofloxacin
found not shown to be safe under the
conditions of use upon the basis of
which the application was approved
as required under § 512(e)(1)(B) of
the Federal Food, Drug, and Cosmetic
Act (the Act) [21 U.S.C. § 360
b(e)(1)(B)]. Approval of NADA1 for
enrofloxacin ordered withdrawn” (1).
The drug manufacturer now is appeal-
ing the ruling.
For the second point, the authors
state that poultry has not been identi-
fied as an important source of fluoro-
quinolone resistance in human
Campylobacter  isolates. In both
Denmark and Spain, introduction of
fluoroquinolones into poultry led to a
rapid rise in resistance to
Campylobacter  in both poultry and
human isolates (2–5), and banning
their use in Denmark led to a rapid fall
in resistance (6). Cox and colleagues
may maintain that there is no “proof
of a causal relationship,” but the rela-
tionship is sufficiently strong, tempo-
rally restricted, biologically plausible,
and coherent to convince disinterested
observers, including Judge Davidson
and ourselves, otherwise. 
For the third point, that decisions
must consider probable consequences,
we agree. However, Cox et al. appear
to use “possible” as their standard. In
fact, nearly everything is possible,
including the reasoning that they
offer. However, in our opinion, based
on experience as scientists and micro-
biologists, we deem the possible con-
sequences described by Cox et al. as
insubstantial compared to the clear
and present danger to human health of
continuing fluoroquinolone use in
poultry. Obfuscation and delay have
been effective tactics used to maintain
profitability even when the facts indi-
cate a different course of action. We
hope that the FDACommissioner will
carefully weigh the actual evidence of
the risk to human health imposed by
the use of fluoroquinolones in poultry.
Nicole M. Iovine* 
and Martin J. Blaser*†
*New York University School of Medicine,
New York, NY, USA; and †New York Harbor
Department of Veterans Affairs Medical
Center, New York, NY, USA
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